多西紫杉醇为主的联合方案治疗晚期乳腺癌的临床观察  

Clinical observation of combination chemotherapy based on docetaxel in the treatment of advanced breast cancer

作　　者：闫红艳[1] 李莉[1] 

机构地区：[1]丹东市中心医院,辽宁丹东118002

出　　处：《中国医疗前沿》2009年第3期29-30,共2页China Healthcare Innovation

摘　　要：目的观察多西紫杉醇为主的联合方案治疗晚期乳腺癌的疗效及不良反应。方法晚期乳腺癌患者52例中,35例既往使用蒽环类治疗失败,予多西紫杉醇联合顺铂化疗或多西紫杉醇联合希罗达化疗,17例既往未曾采用蒽环类治疗,予多西紫杉醇联合表阿霉素化疗。21天为1周期,2周期后评价疗效,有效者化疗6周期。结果52例中CR6例,PR28例,SD10例,PD8例,总有效率为65.4%(34/52)。中位疾病进展进间(TTP)8.2个月,中位生存时间(MST)17.6个月。不良反应主要为骨髓抑制、消化道反应及脱发,但均可耐受,无化疗相关死亡。结论多西紫杉醇为主的联合化疗方案治疗晚期乳腺癌疗效较好,不良反应可耐受。Objective To evaluate the efficacy and toxicity of docetaxel-based combination chemotherapy to patients with advanced breast cancer. Methods The fifty-two patients with advanced breast cancer, thirty-five patients previously failured to adriamycin-based chemotherapy received the regimen of docetaxel plus cisplatin or xeloda, the others received docetaxel plus epirubicin, at least two cycles were given for the patient. The regimen was repeated every 21 days and the clinical response was assessed after two cycles. The effective patients recieved six cycles. Results CR 6 cases, PR 28 cases, SD 10 cases, and PD 8 cases, the overall response rate was 65.4% （34/52）. The main toxicities included myelosuppression, nausea ,vomiting, and alopecia, but they were tolerable. There were no any deaths during treatment. Conclusion The regimen based on docetaxel is effective in the treatment of patients with advanced breast cancer and toxicities are tolerable.

关 键 词：多西紫杉醇 表阿霉素 顺铂 希罗达 化疗 晚期乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]